サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1588942

非小細胞肺がん（NSCLC）治療薬の世界市場

Non-Small Cell Lung Cancer (NSCLC) Therapeutics

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.06円
非小細胞肺がん（NSCLC）治療薬の世界市場
出版日: 2024年11月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非小細胞肺がん（NSCLC）治療薬の世界市場は2030年までに540億米ドルに達する見込み

2023年に304億米ドルと推定された非小細胞肺がん（NSCLC）治療薬の世界市場は、分析期間2023-2030年にCAGR 8.5%で成長し、2030年には540億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 9.6%を記録し、分析期間終了時には313億米ドルに達すると予測されます。免疫療法分野の成長率は、分析期間中CAGR 7.5%と推定されます。

米国市場は79億米ドルと推定、中国はCAGR 12.9％で成長予測

米国の非小細胞肺がん（NSCLC）治療薬市場は2023年に79億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに141億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは12.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と7.5%と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の非小細胞肺がん（NSCLC）治療薬市場- 主要動向と促進要因のまとめ

がん領域で非小細胞肺がん（NSCLC）治療薬が重要な理由

非小細胞肺がん（NSCLC）は最も一般的な肺がんの一種であり、世界全体の肺がん患者の約85%を占めています。NSCLC治療薬は、特定の遺伝子変異を標的とし、患者の生存率を向上させ、従来の化学療法に伴う副作用を軽減するように設計されています。治療法には、手術、放射線療法、化学療法、標的療法、免疫療法などがあり、後者の2つは進行期NSCLCの予後改善に大きな可能性を示しています。肺がんの世界の負担が増加し続ける中、NSCLC治療薬は腫瘍学の焦点となっており、患者により個別化された治療選択肢を提供しています。

NSCLC治療薬市場の主要セグメントは？

主な治療タイプには、化学療法、標的療法、免疫療法、併用療法があり、標的療法と免疫療法はNSCLCの特定の遺伝子サブタイプに有効であることから急成長を遂げています。薬剤クラス別では、EGFR阻害剤、ALK阻害剤、PD-1/PD-L1阻害剤、VEGF阻害剤などがあります。EGFR変異やALK変異を標的とするような変異特異的治療薬は、患者の無増悪生存期間を延長することに特に成功しています。主なエンドユーザーには、病院、がん治療センター、研究機関が含まれ、これらすべてがNSCLC管理プロトコールにこれらの先進治療を組み込んでいます。

NSCLC治療薬はどのようにがん治療を変革しているのか？

病院や腫瘍センターでは、遺伝子検査やバイオマーカー解析によって個別化された治療計画にNSCLC治療薬を組み込んでいます。EGFR阻害剤やALK阻害剤のような標的治療は、しばしば特定の変異を有する患者に処方され、従来の化学療法と比較して副作用が少なく、より効果的な治療を提供しています。PD-1/PD-L1阻害剤などの免疫療法は、ファーストラインとセカンドラインの両方で使用され、進行NSCLC症例の生存成績を向上させています。研究機関や製薬会社は、NSCLCに対する有効な治療法の幅を広げるため、積極的に新薬を開発し、臨床試験を実施しています。さらに、標的薬剤と免疫療法を統合した併用療法は、患者の転帰を改善し、単剤治療に対する耐性を管理する上で有望な結果を示しています。

NSCLC治療薬市場の成長を促す要因は何か？

NSCLC治療薬市場の成長は、肺がんの有病率の増加、効果的な治療オプションへの需要の高まりなど、いくつかの要因によって牽引されています。ゲノミクスと個別化医療の進歩により標的治療の開発が加速し、特定のNSCLCサブタイプに対するより正確な治療が可能になった。生存率の改善における免疫療法の成功は、革新的なNSCLC治療薬の採用をさらに後押ししています。規制当局の承認や研究イニシアチブの拡大も、新規治療薬の市場参入を促進しています。遺伝子検査やバイオマーカー同定に対する意識の高まりが標的療法の採用を促進し、市場の成長に寄与しています。さらに、がん研究に対する政府の資金援助や投資が新規治療法の開発を後押ししており、NSCLC治療薬は腫瘍学において急速に発展している分野となっています。

調査対象企業の例（注目の34社）

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Novartis
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP22390

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach US$54.0 Billion by 2030

The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$30.4 Billion in the year 2023, is expected to reach US$54.0 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$31.3 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.9 Billion While China is Forecast to Grow at 12.9% CAGR

The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$7.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market - Key Trends and Drivers Summarized

Why Are Non-Small Cell Lung Cancer (NSCLC) Therapeutics Crucial in Oncology?

Non-Small Cell Lung Cancer (NSCLC) represents the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases globally. NSCLC therapeutics are designed to target specific genetic mutations, improve patient survival rates, and reduce the side effects associated with traditional chemotherapy. Treatment modalities include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with the latter two showing significant promise in improving outcomes for advanced-stage NSCLC. As the global burden of lung cancer continues to rise, NSCLC therapeutics have become a focal point in oncology, providing more personalized treatment options for patients.

What Are the Key Segments in the NSCLC Therapeutics Market?

Key treatment types include chemotherapy, targeted therapy, immunotherapy, and combination therapy, with targeted and immunotherapies experiencing rapid growth due to their effectiveness in specific genetic subtypes of NSCLC. In terms of drug class, the market includes EGFR inhibitors, ALK inhibitors, PD-1/PD-L1 inhibitors, and VEGF inhibitors, among others. Mutation-specific therapies, such as those targeting EGFR and ALK mutations, have been particularly successful in extending progression-free survival in patients. Major end-users include hospitals, cancer treatment centers, and research institutes, all of which are incorporating these advanced therapies into NSCLC management protocols.

How Are NSCLC Therapeutics Transforming Cancer Care?

Hospitals and oncology centers are integrating NSCLC therapeutics into personalized treatment plans, guided by genetic testing and biomarker analysis. Targeted therapies, such as EGFR inhibitors and ALK inhibitors, are often prescribed for patients with specific mutations, offering more effective treatment with fewer side effects compared to traditional chemotherapy. Immunotherapies, such as PD-1/PD-L1 inhibitors, are being used in both first-line and second-line settings, enhancing survival outcomes in advanced NSCLC cases. Research institutes and pharmaceutical companies are actively developing new drugs and conducting clinical trials to expand the range of effective treatments for NSCLC. Additionally, combination therapies that integrate targeted agents with immunotherapy are showing promising results in improving patient outcomes and managing resistance to single-drug treatments.

What Factors Are Driving the Growth in the NSCLC Therapeutics Market?

The growth in the NSCLC Therapeutics market is driven by several factors, including the increasing prevalence of lung cancer, which has intensified the demand for effective treatment options. Advances in genomics and personalized medicine have accelerated the development of targeted therapies, allowing for more precise treatment of specific NSCLC subtypes. The success of immunotherapy in improving survival rates has further propelled the adoption of innovative NSCLC drugs. Regulatory approvals and expanding research initiatives have also facilitated the entry of new therapeutics into the market. The growing awareness of genetic testing and biomarker identification has enhanced the adoption of targeted therapies, contributing to market growth. Additionally, government funding and investments in cancer research have supported the development of novel treatments, making NSCLC therapeutics a rapidly evolving field in oncology.

Select Competitors (Total 34 Featured) -

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline plc
  • Novartis
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted and Immuno-Oncology Therapies Spurs Growth in NSCLC Therapeutics Market
    • Technological Advancements in Biomarker Discovery and Genomic Profiling Strengthen Business Case for Adoption
    • Growing Focus on Precision Medicine and Personalized Treatment Expands Addressable Market for NSCLC Therapeutics
    • Expansion of NSCLC Therapeutics in Hospitals, Cancer Centers, and Specialty Clinics Fuels Market Growth
    • Increasing Adoption of NSCLC Therapeutics in Adjuvant, Neoadjuvant, and Palliative Settings Expands Market Opportunities
    • Technological Innovations in Monoclonal Antibodies, PD-1/PD-L1 Inhibitors, and EGFR-TKIs Propel Market Expansion
    • Growing Use of Combination Therapies in Advanced and Metastatic NSCLC Expands Market Potential
    • Focus on Meeting Reimbursement Policies and Expanding Access to Novel NSCLC Drugs Strengthens Market for Therapeutics
    • Technological Advancements in Liquid Biopsy and ctDNA Analysis Propel Market Growth
    • Increasing Focus on Integrating NSCLC Therapies with Digital Health Platforms and Remote Monitoring Drives Adoption
    • Rising Demand for NSCLC Therapeutics in Immunotherapy and Chemotherapy-Resistant Cases Strengthens Global Market
    • Expansion of NSCLC Therapeutics in First-Line, Second-Line, and Maintenance Therapies Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Squamous Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Large Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • JAPAN
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • CHINA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • EUROPE
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • FRANCE
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • GERMANY
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • INDIA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030
  • AFRICA
    • Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2024 & 2030

IV. COMPETITION